Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma

Xiong, Ke-Gong; Lin, Tai-Shun; Kong, Jinfeng; Lin, Qing-Biao; Chen, Lifang; Ke, Kun-Yu

doi:10.1097/md.0000000000033062

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Після резекцій 65-70 % і більше паренхіми печінки її функції можуть відновлюватися за рахунок збільшення об'єму шляхом регенерації [2]. Проте, одним із післяопераційних ускладнень гепатектомії є малий розмір й функціонально нездатний печінковий залишок [3]. Тому, для стимуляції проліферативних і репаративних процесів у печінковому залишку може бути ефективне застосування аутомезоконцентрату тромбоцитів (АМК) [4].…”

Section: вступunclassified

The Effect of Automesoconcentrate of Platelets on the Stages of Regeneration of the Liver Remnant of Rats Under the Conditions of Performing Volumetric Experimental Liver Resections

Salyutin,

Yuzvyk

2024

Clin. and prev. med.

View full text Add to dashboard Cite

Introduction. Liver regeneration occurs in three stages, each of which is regulated by different factors: the initiation phase is regulated by interleukin 6 (IL-6) and tumor necrosis factor (TNFα); expansion phase – by hepatocyte growth factor (HGF) and transforming growth factor alpha (TGFα); the terminal phase – transforming growth factor beta (TGFβ) and activins. The work determined the level of markers of the main stages of liver regeneration after resection of 65-70% of the parenchyma of this organ in rats under the conditions of using different doses and schemes of administration of automesoconcentrate of platelets (AMС). The purpose of the study is to establish the characteristics of changes in the level of cytokines and growth factors in the homogenate of the liver of rats after resection of 65-70% of the parenchyma of this organ under the conditions of the use of different doses and schemes of AMС administration. Materials and methods. The study was conducted on white Wistar rats aged 1.5-2 months, weighing 150-180 g. AMС was injected: into the parenchyma of the liver remnant during resection at a dose of 0.5 ml/kg (group I); into the tail vein in the postoperative period at a dose of 0.5 ml/kg 3 hours and 48 hours after liver resection (group II); into the tail vein in the postoperative period at a dose of 1.0 ml/kg 3 hours and 48 hours after resection. Research results and discussion. It was shown that on the 7th day after liver resection, the level of TNF-α and IL-6 increased in all experimental groups, followed by a decrease on the 10th day to control values in the group of animals that received AMA intravenously at a dose of 1 ml/kg masses of animals. It was established that the values of HGF and TGFα in the liver homogenate of animals that underwent liver resection were significantly higher than in the control group on the 7th day of the experiment. At the later stages of the experiment, a decrease in the levels of HGF and TGFα in the liver homogenate was observed in the animals of groups I and III, but the studied indicators did not reach control values. In animals of group II, indicators of HGF and TGFα content remained at the highest level. The increase in the content of TGFβ and activins in the homogenate of the liver of rats in all experimental groups indicates the intensification of the terminal phase of liver regeneration on the 10th day after liver resection. Conclusions. Therefore, under the action of a dose of АМС equal to 1 ml/kg, the regeneration processes occur most intensively, the peak of which occurs 7-10 days after the resection. Administration of AMA into the liver parenchyma at a lower dose of 0.5 ml/kg or intravenous administration of the same dose does not contribute to the complete restoration of regenerative processes in the liver, as indicated by increased levels of TGFα and HGF on the 10th day after liver resection and administration of AMA.

show abstract

Section: вступunclassified

The Effect of Automesoconcentrate of Platelets on the Stages of Regeneration of the Liver Remnant of Rats Under the Conditions of Performing Volumetric Experimental Liver Resections

Salyutin,

Yuzvyk

2024

Clin. and prev. med.

View full text Add to dashboard Cite

show abstract

“…An Italian Liver Cancer Center study showed that out of 6882 patients diagnosed with HCC, 4706 (68.4%) patients were found to have MAFLD [13]. A Chinese study showed that among 514 HBV-HCC patients who underwent radical resection, MAFLD was detected in 117 (22.8%) patients [14]. MAFLD serves as a significant risk factor for the development of HCC and warrants careful consideration from clinicians regarding its potential impact on post-hepatectomy complications.…”

Section: Introductionmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma

Xiong,

Ke,

Kong

et al. 2024

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Background and aims The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in hepatocellular carcinoma (HCC) patients is increasing, yet its association with postoperative complications of HCC remains unclear. The aim of this study was to investigate the impact of MAFLD on complications after radical resection in HCC patients. Methods Patients with HCC who underwent radical resection were included. Patients were stratified into MAFLD group and non-MAFLD group. Clinical features and post-hepatectomy complications were compared between the two groups, and logistic regression analysis was used to determine independent risk factors associated with post-hepatectomy complications. Results Among the 936 eligible patients with HCC who underwent radical resection, concurrent MAFLD was diagnosed in 201 (21.5%) patients. Compared to the non-MAFLD group, the MAFLD group exhibited a higher incidence of complications, including infectious and major complications after radical resection in HCC patients. The logistic regression analysis found that MAFLD was an independent risk factor for complications, including infectious and major complications in HCC patients following radical resection (OR 1.565, 95%CI 1.109–2.343, P = 0.012; OR 2.092, 95%CI 1.386–3.156, P < 0.001; OR 1.859, 95% CI 1.106–3.124, P = 0.019; respectively). Subgroup analysis of HBV-related HCC patients yielded similar findings, and MAFLD patients with type 2 diabetes mellitus (T2DM) exhibited a higher incidence of postoperative complications compared to those without T2DM (all P < 0.05). Conclusions Concurrent MAFLD was associated with an increased incidence of complications after radical resection in patients with HCC, especially MAFLD with T2DM.

show abstract

“…An Italian Liver Cancer Center study showed that out of 6882 patients diagnosed with HCC, 4706 (68.4%) patients were found to have MAFLD [13]. A Chinese study showed that among 514 HBV-HCC patients who underwent radical resection, MAFLD was detected in 117 (22.8%) patients [14]. MAFLD serves as a signi cant risk factor for the development of HCC and warrants careful consideration from clinicians regarding its potential impact on posthepatectomy complications.…”

Section: Introductionmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma

Xiong,

Ke,

Kong

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background and aims: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in hepatocellular carcinoma (HCC) patients is increasing, yet its association with postoperative complications of HCC remains unclear. The aim of this study was to investigate the impact of MAFLD on complications after radical resection in HCC patients. Methods Patients with HCC who underwent radical resection were included. Patients were stratified into MAFLD group and non-MAFLD group. Clinical features and post-hepatectomy complications were compared between the two groups, and logistic regression analysis was used to determine independent risk factors associated with post-hepatectomy complications. Results Among the 936 eligible patients with HCC who underwent radical resection, concurrent MAFLD was diagnosed in 201 (21.5%) patients. Compared to the non-MAFLD group, the MAFLD group exhibited a higher incidence of complications, including infectious and major complications after radical resection in HCC patients. The logistic regression analysis found that MAFLD was an independent risk factor for complications, including infectious and major complications in HCC patients following radical resection (OR 1.565, 95%CI 1.109–2.343, P = 0.012; OR 2.092, 95%CI 1.386–3.156, P < 0.001; OR 1.859, 95% CI 1.106–3.124, P = 0.019; respectively). Subgroup analysis of HBV-related HCC patients yielded similar findings, and MAFLD patients with type 2 diabetes mellitus (T2DM) exhibited a higher incidence of postoperative complications compared to those without T2DM (all P < 0.05). Conclusions Concurrent MAFLD was associated with an increased incidence of complications after radical resection in patients with HCC, especially MAFLD with T2DM.

show abstract

Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma

Cited by 3 publications

References 34 publications

The Effect of Automesoconcentrate of Platelets on the Stages of Regeneration of the Liver Remnant of Rats Under the Conditions of Performing Volumetric Experimental Liver Resections

The Effect of Automesoconcentrate of Platelets on the Stages of Regeneration of the Liver Remnant of Rats Under the Conditions of Performing Volumetric Experimental Liver Resections

Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma

Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma

Contact Info

Product

Resources

About